Check-Cap is aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect precancerous polyps and help with early intervention and cancer prevention. The company’s disruptive capsule-based screening technology aims to drastically increase screening adherence worldwide and help millions of people get the preventive CRC screening they need. The technology has been evaluated in a pilot study in the U.S. and has received regulatory approval for marketing in the EU and Israel. Data from clinical trials showed promising results, including safety, high patient compliance, and high sensitivity at detecting precancerous polyps when the technology was compared to the FIT test. Colonoscopy was used as the reference method. Check-Cap is evaluating C-Scan® as part of an ongoing pivotal study in the U.S., designed to obtain FDA approval for C-Scan® in the U.S.
The C-Scan® System utilizes a low dose X-ray capsule, an integrated positioning, control, and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon. C-Scan® is patient-friendly and requires no cathartic preparation or sedation, allowing the patients to continue their daily routine with little to no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.
Market quotes provided by Quote Media. All quotes are delayed at least 15 minutes. All times are ET. Learn more at Stock Information